Sequencing of Cabazitaxel in Metastatic Castrate-Resistant Prostate Cancer: A Case Report
Prostate cancer is a common cancer in men; for metastatic disease, it has a 5-year survival rate of 30%. No FDA-approved therapy for castrate-resistant prostate cancer (CRPC) known to improve survival was available until 2004, when based on a significant survival benefit over mitoxantrone, docetaxel...
Na minha lista:
| Autor principal: | |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Karger Publishers
2012-06-01
|
| coleção: | Case Reports in Oncology |
| Assuntos: | |
| Acesso em linha: | http://www.karger.com/Article/FullText/339576 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|